JP5897592B2 - 葉酸−ラミプリルの組合せ:細胞保護性、神経保護性、および網膜保護性の眼科用組成物 - Google Patents
葉酸−ラミプリルの組合せ:細胞保護性、神経保護性、および網膜保護性の眼科用組成物 Download PDFInfo
- Publication number
- JP5897592B2 JP5897592B2 JP2013541436A JP2013541436A JP5897592B2 JP 5897592 B2 JP5897592 B2 JP 5897592B2 JP 2013541436 A JP2013541436 A JP 2013541436A JP 2013541436 A JP2013541436 A JP 2013541436A JP 5897592 B2 JP5897592 B2 JP 5897592B2
- Authority
- JP
- Japan
- Prior art keywords
- active ingredient
- vitamin
- folic acid
- composition
- ramipril
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 183
- 229960003401 ramipril Drugs 0.000 title claims description 42
- 230000002207 retinal effect Effects 0.000 title claims description 15
- 230000001681 protective effect Effects 0.000 title description 12
- 230000000324 neuroprotective effect Effects 0.000 title description 11
- 230000001120 cytoprotective effect Effects 0.000 title description 10
- 239000004480 active ingredient Substances 0.000 claims description 173
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 128
- 239000011724 folic acid Substances 0.000 claims description 79
- 235000019152 folic acid Nutrition 0.000 claims description 78
- 239000003814 drug Substances 0.000 claims description 58
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 50
- 229960000304 folic acid Drugs 0.000 claims description 50
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 46
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 44
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 40
- 239000011777 magnesium Substances 0.000 claims description 30
- 229910052749 magnesium Inorganic materials 0.000 claims description 30
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 28
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 28
- 229940014144 folate Drugs 0.000 claims description 28
- 235000001055 magnesium Nutrition 0.000 claims description 28
- 239000011591 potassium Substances 0.000 claims description 28
- 229910052700 potassium Inorganic materials 0.000 claims description 28
- 235000007686 potassium Nutrition 0.000 claims description 28
- 239000008103 glucose Substances 0.000 claims description 27
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 26
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 24
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 claims description 24
- 229930003268 Vitamin C Natural products 0.000 claims description 24
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 24
- 239000003889 eye drop Substances 0.000 claims description 24
- 235000019154 vitamin C Nutrition 0.000 claims description 24
- 239000011718 vitamin C Substances 0.000 claims description 24
- 229960000669 acetylleucine Drugs 0.000 claims description 23
- 239000002997 ophthalmic solution Substances 0.000 claims description 22
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 21
- 235000014852 L-arginine Nutrition 0.000 claims description 21
- 229930064664 L-arginine Natural products 0.000 claims description 21
- 239000002876 beta blocker Substances 0.000 claims description 21
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 21
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 21
- 229930003779 Vitamin B12 Natural products 0.000 claims description 20
- 229940097320 beta blocking agent Drugs 0.000 claims description 20
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 20
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 20
- KEDYTOTWMPBSLG-HILJTLORSA-N ramiprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 KEDYTOTWMPBSLG-HILJTLORSA-N 0.000 claims description 20
- 235000019163 vitamin B12 Nutrition 0.000 claims description 20
- 239000011715 vitamin B12 Substances 0.000 claims description 20
- 235000019158 vitamin B6 Nutrition 0.000 claims description 20
- 239000011726 vitamin B6 Substances 0.000 claims description 20
- 229940011671 vitamin b6 Drugs 0.000 claims description 20
- -1 c) Optionally Substances 0.000 claims description 18
- 235000001014 amino acid Nutrition 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 239000006014 omega-3 oil Substances 0.000 claims description 18
- 229940054534 ophthalmic solution Drugs 0.000 claims description 18
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 17
- 229960002748 norepinephrine Drugs 0.000 claims description 15
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 15
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000000464 adrenergic agent Substances 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 13
- 229940012356 eye drops Drugs 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 10
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 10
- 235000001727 glucose Nutrition 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000002674 ointment Substances 0.000 claims description 10
- 208000027073 Stargardt disease Diseases 0.000 claims description 9
- 210000001525 retina Anatomy 0.000 claims description 8
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 5
- 230000001800 adrenalinergic effect Effects 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 238000011200 topical administration Methods 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 201000007737 Retinal degeneration Diseases 0.000 claims description 2
- 125000003929 folic acid group Chemical group 0.000 claims description 2
- 229960002231 ramiprilat Drugs 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 55
- 238000000034 method Methods 0.000 description 53
- 241001465754 Metazoa Species 0.000 description 41
- 230000004438 eyesight Effects 0.000 description 39
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 29
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 28
- 201000010099 disease Diseases 0.000 description 28
- 229960003136 leucine Drugs 0.000 description 28
- 208000035475 disorder Diseases 0.000 description 27
- 230000004393 visual impairment Effects 0.000 description 25
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 24
- 239000003981 vehicle Substances 0.000 description 17
- 230000000007 visual effect Effects 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 230000032683 aging Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 201000004569 Blindness Diseases 0.000 description 12
- WXNXCEHXYPACJF-UHFFFAOYSA-N N-acetyl-leucine Chemical compound CC(C)CC(C(O)=O)NC(C)=O WXNXCEHXYPACJF-UHFFFAOYSA-N 0.000 description 12
- ZHQJVZLJDXWFFX-RPDRRWSUSA-N (6R)-L-erythro-6,7-dihydrobiopterin Chemical compound N1C(N)=NC(=O)C2=N[C@@H]([C@@H](O)[C@@H](O)C)CN=C21 ZHQJVZLJDXWFFX-RPDRRWSUSA-N 0.000 description 11
- 208000030533 eye disease Diseases 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 239000000556 agonist Substances 0.000 description 10
- 208000001491 myopia Diseases 0.000 description 10
- 230000004382 visual function Effects 0.000 description 10
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 9
- 206010064930 age-related macular degeneration Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 9
- 208000010412 Glaucoma Diseases 0.000 description 8
- 229960003679 brimonidine Drugs 0.000 description 8
- 201000010041 presbyopia Diseases 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- 230000004304 visual acuity Effects 0.000 description 8
- 206010012689 Diabetic retinopathy Diseases 0.000 description 7
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 7
- 206010013774 Dry eye Diseases 0.000 description 7
- 229960001031 glucose Drugs 0.000 description 7
- 206010023332 keratitis Diseases 0.000 description 7
- 201000010666 keratoconjunctivitis Diseases 0.000 description 7
- 208000002780 macular degeneration Diseases 0.000 description 7
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 6
- 239000005541 ACE inhibitor Substances 0.000 description 6
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 6
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 208000018769 loss of vision Diseases 0.000 description 6
- 231100000864 loss of vision Toxicity 0.000 description 6
- 229940091250 magnesium supplement Drugs 0.000 description 6
- 230000004379 myopia Effects 0.000 description 6
- 201000001119 neuropathy Diseases 0.000 description 6
- 230000007823 neuropathy Effects 0.000 description 6
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 6
- 208000033808 peripheral neuropathy Diseases 0.000 description 6
- 229960003975 potassium Drugs 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229960004605 timolol Drugs 0.000 description 6
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 210000001742 aqueous humor Anatomy 0.000 description 5
- 239000006196 drop Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 229930182837 (R)-adrenaline Natural products 0.000 description 4
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- 206010046851 Uveitis Diseases 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 229960002610 apraclonidine Drugs 0.000 description 4
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 4
- 208000037849 arterial hypertension Diseases 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 229960000397 bevacizumab Drugs 0.000 description 4
- 229960002896 clonidine Drugs 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 229960005139 epinephrine Drugs 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004410 intraocular pressure Effects 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 229960003876 ranibizumab Drugs 0.000 description 4
- 208000004644 retinal vein occlusion Diseases 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 201000007527 Retinal artery occlusion Diseases 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002137 anti-vascular effect Effects 0.000 description 3
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 3
- 229960002781 bisoprolol Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004456 color vision Effects 0.000 description 3
- 208000021921 corneal disease Diseases 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 230000004377 improving vision Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 159000000003 magnesium salts Chemical class 0.000 description 3
- 230000000626 neurodegenerative effect Effects 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 229960001528 oxymetazoline Drugs 0.000 description 3
- 229960003407 pegaptanib Drugs 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 235000019159 vitamin B9 Nutrition 0.000 description 3
- 239000011727 vitamin B9 Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102400000967 Bradykinin Human genes 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- 208000033379 Chorioretinopathy Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 description 2
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 2
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 206010020675 Hypermetropia Diseases 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 2
- WXNXCEHXYPACJF-SSDOTTSWSA-N N-acetyl-D-leucine Chemical compound CC(C)C[C@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-SSDOTTSWSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 208000001140 Night Blindness Diseases 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 201000010183 Papilledema Diseases 0.000 description 2
- 206010033708 Papillitis Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 102000014384 Type C Phospholipases Human genes 0.000 description 2
- 108010079194 Type C Phospholipases Proteins 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 229930003761 Vitamin B9 Natural products 0.000 description 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 2
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 2
- 229960002122 acebutolol Drugs 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 229960002274 atenolol Drugs 0.000 description 2
- 229960004324 betaxolol Drugs 0.000 description 2
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 229960001222 carteolol Drugs 0.000 description 2
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 2
- 229960003745 esmolol Drugs 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 229960004553 guanabenz Drugs 0.000 description 2
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 2
- 229960003602 guanethidine Drugs 0.000 description 2
- 229960002048 guanfacine Drugs 0.000 description 2
- QKIQJNNDIWGVEH-UUILKARUSA-N guanoxabenz Chemical compound ONC(/N)=N/N=C/C1=C(Cl)C=CC=C1Cl QKIQJNNDIWGVEH-UUILKARUSA-N 0.000 description 2
- 229960001016 guanoxabenz Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000004305 hyperopia Effects 0.000 description 2
- 201000006318 hyperopia Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960001632 labetalol Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 2
- 229960000831 levobunolol Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 229960005192 methoxamine Drugs 0.000 description 2
- 229960002704 metipranolol Drugs 0.000 description 2
- BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- 229960004255 nadolol Drugs 0.000 description 2
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000013441 ocular lesion Diseases 0.000 description 2
- 229940069265 ophthalmic ointment Drugs 0.000 description 2
- 201000002166 optic papillitis Diseases 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 2
- 229960002035 penbutolol Drugs 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229950010765 pivalate Drugs 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 230000001012 protector Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 2
- 229960004617 sapropterin Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 2
- 229960002370 sotalol Drugs 0.000 description 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 2
- 229960000488 tizanidine Drugs 0.000 description 2
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- MEZCUMCMVYZPAH-UHFFFAOYSA-N 6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CC(F)C2=C1 MEZCUMCMVYZPAH-UHFFFAOYSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000014087 Chorioretinal disease Diseases 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- LHQIJBMDNUYRAM-AWFVSMACSA-N D-erythro-biopterin Chemical compound N1=C(N)NC(=O)C2=NC([C@H](O)[C@H](O)C)=CN=C21 LHQIJBMDNUYRAM-AWFVSMACSA-N 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010019899 Hereditary retinal dystrophy Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- LHQIJBMDNUYRAM-UHFFFAOYSA-N L-erythro-Biopterin Natural products N1=C(N)NC(=O)C2=NC(C(O)C(O)C)=CN=C21 LHQIJBMDNUYRAM-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 206010038903 Retinal vascular occlusion Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229940003677 alphagan Drugs 0.000 description 1
- 229940077927 altace Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 239000003920 antivertigo agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000016967 beta-1 Adrenergic Receptors Human genes 0.000 description 1
- 108010014494 beta-1 Adrenergic Receptors Proteins 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 description 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 201000005849 central retinal artery occlusion Diseases 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 210000003717 douglas' pouch Anatomy 0.000 description 1
- 229960001850 droxicam Drugs 0.000 description 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 206010015907 eye allergy Diseases 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229940064302 folacin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004402 high myopia Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229940092110 macugen Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000001067 neuroprotector Effects 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 150000003218 pyrazolidines Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960000337 tetryzoline Drugs 0.000 description 1
- 229940035274 tobradex Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 229960000833 xylometazoline Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
Description
1-緑内障そのものを含む緑内障性神経障害、
2-退行性脈絡網膜症、
3-加齢黄斑変性症(ARMD)、
4-網膜の遺伝性ジストロフィー(網膜色素変性およびシュタルガルト黄斑変性症を含む)、
5-網膜血管閉塞症、
6-近視、
7-老眼、
8-ブドウ膜炎、
9-糖尿病性網膜症、
10-角膜障害、例えば角結膜炎、眼乾燥症候群、またはフックス角膜ジストロフィー、および
11-生理的な視覚低下。
-緑内障性神経障害または緑内障、
-脈絡膜の新生血管を伴うまたは伴わない、黄斑変性症、特にARMD、
-糖尿病性網膜症、
-退行性脈絡網膜症、
-網膜および色素上皮の遺伝性ジストロフィー、例えば網膜色素変性、またはシュタルガルト黄斑変性症(またはシュタルガルト病)、
-網膜動脈閉塞症(特に、網膜中心動脈閉塞症)、
-網膜静脈閉塞症(特に、網膜中心静脈閉塞症または網膜静脈分枝閉塞症)、
-ブドウ膜炎(特に、前部ブドウ膜炎および/または後部ブドウ膜炎)、
-乳頭炎、
-非正常視(ammetropia)、例えば近視(高度近視を含む)、老眼または遠視、
-角膜障害、例えば角結膜炎(とりわけ、眼乾燥症候群によって引き起こされる角結膜炎で、乾性角結膜炎とも呼ばれる)、眼乾燥症候群、またはフックス角膜ジストロフィー、
-眼アレルギー(結膜炎)、
-加齢性の視覚低下、
-視覚の自然喪失(とりわけ、視力および/または視覚範囲の自然な低下)、特に生理的な視覚減退、ならびに
-夜間視覚減退、とりわけ夜盲。
本発明の一実施形態では、本明細書で組成物1と称する本発明の組成物は以下のものを含む、以下のものから本質的になる、または以下のものからなる。
a)ACEIを含む、ACEIから本質的になる、またはACEIからなる、第1の有効成分、および
b)-葉酸、フォレート、マグネシウム、カリウム、グルコース、アミノ酸(例えば、ロイシン、とりわけアセチル-ロイシン)、薬学的に許容されるそれらの塩の1つまたはそれらの誘導体、およびそれらの混合物から選択され、特に、
-葉酸、フォレート、グルコース、アミノ酸(例えばロイシン、とりわけアセチル-ロイシン)、薬学的に許容されるそれらの塩の1つまたはそれらの誘導体、およびそれらの混合物から選択される、第2の有効成分(または、第2の有効成分混合物)、および
c)任意選択的に、L-アルギニン、H4b、ビタミンB6、ビタミンB12、ビタミンC、ω-3脂肪酸、抗炎症剤、β遮断剤、アドレナリン、ノルアドレナリン、αアドレナリン作動剤、抗VEGF剤、薬学的に許容されるそれらの塩の1つまたはそれらの誘導体、およびそれらの混合物から選択される第3の有効成分。
-ラミプリルおよび葉酸と、
-任意選択的に、マグネシウムもしくは薬学的に許容されるその塩、および/またはカリウムもしくは薬学的に許容されるその塩と、
-任意選択的に、本明細書に開示される第3の有効成分、とりわけL-アルギニン、H4b、ビタミンB6、ビタミンB12、ビタミンCおよびω-3脂肪酸の中から選択される第3の有効成分と
を含む、これらから本質的になる、またはこれらからなる。
-葉酸および/またはフォレートと、
-マグネシウム(または薬学的に許容されるその塩)、および/またはカリウム(または薬学的に許容されるその塩)と、
-グルコースおよび/またはアミノ酸(特に、本明細書に開示されるロイシン)、例えば、本明細書に開示されるグルコースおよびロイシンと、
を含む、これらから本質的になる、またはこれらからなる。
「B6および/またはB12および/またはC」とは、ビタミンB6もしくはビタミンB12もしくはビタミンC、またはビタミンB6とビタミンB12、またはビタミンB6とビタミンC、またはビタミンB12とビタミンC、またはビタミンB6とビタミンB12とビタミンCを意味する。
「β遮断薬および/またはαアドレナリン作動薬」とは、β遮断剤(例えばチモロール)もしくはαアドレナリン作動剤(例えばブリモニジン)、またはβ遮断剤とαアドレナリン作動剤(例えばチモロールとブリモニジン)を意味する。
「アドレナリンおよび/またはノルアドレナリン」とは、アドレナリンもしくはノルアドレナリン、またはアドレナリンとノルアドレナリンを意味する。
抗炎症剤は、インドメタシンまたはデキサメタゾンとすることができる。抗VEGF剤は、ベバシズマブ、ラニビズマブまたはペガプタニブとすることができる。
本発明の別の実施形態では、本明細書で組成物2と称する本発明の組成物は、
a)葉酸、フォレート、薬学的に許容されるそれらの塩の1つまたはそれらの誘導体、およびそれらの混合物の中から選択される、第1の有効成分(または、第1の有効成分の混合物)と、
b)マグネシウム、カリウム、グルコース、アミノ酸(例えば、ロイシン、とりわけアセチル-ロイシン)、L-アルギニン、H4b、ビタミンB6、ビタミンB12、ビタミンC、ω-3脂肪酸、薬学的に許容されるそれらの塩の1つまたはそれらの誘導体、およびそれらの混合物から選択される第2の有効成分(または、第2の有効成分混合物)と、
c)任意選択的に、抗炎症剤、β遮断剤、アドレナリン、ノルアドレナリン、αアドレナリン作動剤、抗VEGF剤、薬学的に許容されるそれらの塩の1つまたはそれらの誘導体、およびそれらの混合物から選択される第3の有効成分と
を含む、これらから本質的になる、またはこれらからなる。
-マグネシウム(または、薬学的に許容されるその塩)、および/またはカリウム(または、薬学的に許容されるその塩)、および/またはグルコース、および/またはアミノ酸(例えばロイシン、とりわけアセチル-ロイシン)、および/またはL-アルギニンと、
-任意選択的に、H4b、ビタミンB6、ビタミンB12、ビタミンC、ω-3脂肪酸、薬学的に許容されるそれらの塩の1つまたはそれらの誘導体、およびそれらの混合物から選択される有効成分と
を含む、これらから本質的になる、またはこれらからなる。
-第1の有効成分が、葉酸および/またはフォレートを含む、これから本質的になる、またはこれからなり、
-第2の有効成分が、
(i)マグネシウム(または、薬学的に許容されるその塩)、カリウム(または、薬学的に許容されるその塩)、グルコース、および本明細書に開示されるロイシン、例えばN-アセチル-ロイシン、とりわけN-アセチル-DL-ロイシン、または
(ii)マグネシウム(または、薬学的に許容されるその塩)、カリウム(または、薬学的に許容されるその塩)、グルコース、本明細書に開示されるロイシン(例えばN-アセチル-ロイシンとりわけN-アセチル-DL-ロイシン)、およびL-アルギニン
を含む、これらから本質的になる、またはこれらからなり、
-第3の有効成分は、前記組成物の中に存在しているか、または存在していない。
-第1の有効成分が、葉酸および/またはフォレートを含む、これらから本質的になる、またはこれらからなり、
-第2の有効成分が、
(i)マグネシウム(または、薬学的に許容されるその塩)、および/またはカリウム(または、薬学的に許容されるその塩)、および/または本明細書に開示されるロイシン、および/またはグルコースと、
(ii)Table 1(表1)に記載されている化合物の混合物と
を含む、これらから本質的になる、またはこれらからなり、
-第3の有効成分は、前記組成物の中に存在しているか、または存在していない。
本発明の別の実施形態では、本明細書で組成物3と称する本発明の組成物は、
a)グルコース、薬学的に許容されるその塩の1つまたはその誘導体、およびそれらの混合物の中から選択される、第1の有効成分(または、第1の有効成分の混合物)と、
b)マグネシウム、カリウム、薬学的に許容されるその塩の1つまたはそれらの誘導体、およびそれらの混合物の中から選択される、第2の有効成分(または、第2の有効成分の混合物)と、
c)アミノ酸の中から選択される第3の有効成分、例えば、ロイシン、または薬学的に許容される塩もしくはその誘導体、例えばN-アセチル-ロイシン、とりわけN-アセチル-DL-ロイシンを含むまたはそれなる第3の有効成分と
を含む、これらから本質的になる、またはこれらからなる。
-第1の有効成分として、グルコース、
-第2の有効成分として、マグネシウム(または、薬学的に許容されるその塩の1つ)、およびカリウム(または、薬学的に許容されるその塩の1つ)、ならびに、
-第3の有効成分として、本明細書に開示されるロイシン、例えばN-アセチル-ロイシン、とりわけN-アセチル-DL-ロイシン、
を含む、これらから本質的になる、またはこれらからなる。
-ACEI、葉酸、フォレート、マグネシウム、カリウム、グルコース、アミノ酸(とりわけロイシン、特にアセチル-ロイシン)、L-アルギニン、H4b、ビタミンB6、ビタミンB12、ビタミンC、ω-3脂肪酸、抗炎症剤、β遮断剤、アドレナリン、ノルアドレナリン、αアドレナリン作動剤、抗血管内皮増殖因子(抗VEGF)剤、薬学的に許容されるそれらの塩またはそれらの誘導体、ならびにそれらの混合物の中から選択される、複数(少なくとも2種)の有効成分、および
-任意選択的に、前記キットを使用するための指示書、
を含む、またはこれらからなり、
前記有効成分が、同一組成物中に一緒にされているか、またはこれらの有効成分の少なくとも2種が、別個の組成物中に存在している、
キットにも関する。
(i)第1の有効成分と、
(ii)第2の有効成分と、
(iii)任意選択的に、第3の有効成分と、
(iv)任意選択的に、前記キットを使用(例えば、本発明の方法において)するための指示書と
を含むか、これらからなり、
第1の有効成分、第2の有効成分、および存在する場合、第3の有効成分が、組成物1、2もしくは3について本明細書に開示される通りであり、かつ同一組成物中に一緒にされているか、またはこれらの有効成分の少なくとも2種が、別個の組成物中に存在している。
-(i)第3の有効成分が存在しない(この場合、1つの組成物は第1の有効成分を含んでおり、もう一方の組成物は第2の有効成分を含む)、または
(ii)第3の有効成分は存在するが、第1の有効成分、第2の有効成分または第3の有効成分のいずれか1つが、別個の組成物中の他の2種の有効成分とは別になっている、
場合、たった2つの組成物しか別個に含むことができず、
-第3の有効成分が存在し、かつこれら3種の有効成分の各々が別個の組成物中に存在する場合(すなわち、これら3つの組成物の各々が、3種の有効成分の1つおよび薬学的に許容されるビヒクル、とりわけ眼科上許容されるビヒクルを含む、これらから本質的になる、またはこれらからなる)、3つの別個の組成物を含むことができる。
- 0.5〜5%または0.5〜3%の濃度、例えば、0.5%、1%または2%の濃度で局所的(例えば、点眼剤の形態)、および/または
- 0.5〜5mg/日、好ましくは1〜2mg/日、例えば1.25mg/日の量で経口的に
ヒトに投与することができ、また
葉酸またはフォレートを、
- 0.5〜5%または0.5〜3%の濃度、例えば、0.5%、1%または2%の濃度で局所的(例えば、点眼剤の形態)、および/または
- 2〜8mg/日、好ましくは4〜6mg/日、例えば5mg/日の量で経口的に、
ヒトに投与することができる。
以下に開示される臨床事例の場合、有効成分、特にラミプリルおよび葉酸を、ラミプリルに関して1日当たり1.25mgの経口形態、および葉酸に関して1日当たり5mgの経口形態または局所形態で、連続的(すなわち、少なくとも1日1回)に投与した。
網膜および色素上皮の遺伝性ジストロフィー:
1-色素性網膜炎:この障害は、錐状体と桿状体におけるジストロフィーに相当する。それは、幼少期または青年期の夜盲症の発症(appearance)、進行性の周辺視野狭小によって特徴づけられ、成年期までにかなりの視力喪失、または失明さえする。4人の患者を経口的または局所的に治療すると、この患者らの視力が改善された。
2人の患者を治療した。視力は、2/10から4/10に改善された。
Claims (20)
- 網膜の遺伝性ジストロフィーの予防及び/又は治療のための医薬組成物であって、
a)ラミプリル、ラミプリラート、薬学的に許容されるそれらの塩の1つ、またはそれらの混合物の中から選択される、第1の有効成分と、
b)葉酸、フォレート、薬学的に許容されるそれらの塩の1つ、およびそれらの混合物の中から選択される、第2の有効成分と、
c)任意選択的に、マグネシウム、カリウム、グルコース、アミノ酸、L-アルギニン、H4b、ビタミンB6、ビタミンB12、ビタミンC、ω-3脂肪酸、抗炎症剤、β遮断剤、アドレナリン、ノルアドレナリン、αアドレナリン作動剤、抗VEGF剤、薬学的に許容されるそれらの塩、およびこれらの混合物の中から選択される、第3の有効成分と
を含む、医薬組成物。 - 第1の有効成分がラミプリルであり、第2の有効成分が葉酸であり、マグネシウムもしくは薬学的に許容されるその塩および/またはカリウムもしくは薬学的に許容されるその塩をさらに含有する、請求項1に記載の医薬組成物。
- アミノ酸が、アセチル-ロイシンである、請求項1または2に記載の医薬組成物。
- 経腸、経口、非経腸、静脈内、筋肉内、皮下、経皮、局所、またはテノン嚢下投与の中から選択される投与に適した形態である、請求項1から3のいずれか一項に記載の医薬組成物。
- 局所投与が、眼への局所投与、または硝子体内注射である、請求項4に記載の医薬組成物。
- 錠剤、液剤、ローション剤、点滴剤、クリーム剤、または軟膏剤の形態である、請求項1から5のいずれか一項に記載の医薬組成物。
- 眼科用液剤または点眼剤の形態である、請求項1から6のいずれか一項に記載の医薬組成物。
- 網膜色素変性症またはシュタルガルト病である網膜の遺伝性ジストロフィーの予防および/または治療のための、請求項1から7のいずれか一項に記載の医薬組成物を含む眼科的医薬。
- -ラミプリルまたはラミプリラートが、局所投与するのに適しており、0.5〜5%もしくは0.5〜3%の濃度で投薬され、かつ/または0.5〜5mg/日の用量で経口投与するのに適しており、かつ/あるいは、
-葉酸またはフォレートが、ヒトに局所投与するのに適しており、0.5〜5%もしくは0.5〜3%の濃度で投薬され、かつ/またはヒトに2〜8mg/日の用量で経口投与するのに適している、
請求項8に記載の医薬。 - ラミプリルもしくはラミプリラートおよび/または葉酸もしくはフォレートが、点眼剤の形態で局所投与するのに適している、請求項8または9に記載の医薬。
- ラミプリルもしくはラミプリラートおよび/または葉酸もしくはフォレートが、0.5%、1%または2%の中から選択される濃度で投薬される、請求項8から10のいずれか一項に記載の医薬。
- ラミプリルまたはラミプリラートが、1〜2mg/日の用量で経口投与するのに適している、請求項8から11のいずれか一項に記載の医薬。
- 葉酸またはフォレートが、4〜6mg/日の用量で経口投与するのに適している、請求項8から12のいずれか一項に記載の医薬。
- 網膜の遺伝性ジストロフィーの予防及び/又は治療のためのキットであって、
a)ラミプリル、ラミプリラート、薬学的に許容されるそれらの塩の1つ、またはそれらの混合物の中から選択される、第1の有効成分と、
b)葉酸、フォレート、薬学的に許容されるそれらの塩の1つ、およびそれらの混合物の中から選択される、第2の有効成分と、
c)任意選択的に、マグネシウム、カリウム、グルコース、アミノ酸、L-アルギニン、H4b、ビタミンB6、ビタミンB12、ビタミンC、ω-3脂肪酸、抗炎症剤、β遮断剤、アドレナリン、ノルアドレナリン、αアドレナリン作動剤、抗VEGF剤、薬学的に許容されるそれらの塩、およびこれらの混合物の中から選択される、第3の有効成分と
からなり、
任意選択的に前記キットを使用するための指示書をさらに含み、
前記有効成分が同一組成物中に一緒にされているか、またはこれらの有効成分の少なくとも2種が別個の組成物中に存在している、
キット。 - 網膜の遺伝性ジストロフィーの予防及び/又は治療のための医薬の製造のための、請求項1から7のいずれか一項に記載の医薬組成物、または請求項14に記載のキットの使用。
- 網膜色素変性症またはシュタルガルト病の予防または治療用の医薬を製造するための、請求項15に記載の使用。
- 前記医薬の前記有効成分が別個にまたは別個でなく投与される、請求項8から13のいずれか一項に記載の医薬。
- 有効成分が、眼科用液剤、点眼剤もしくは軟膏剤の形態で、かつ/または硝子体内注射によって局所的に投与されることに適し、または、経腸経路により投与されることに適し、または、非経腸経路により投与されることに適する、請求項8から13のいずれか一項に記載の医薬。
- 有効成分が、経口的に投与されることに適する、請求項18に記載の医薬。
- 有効成分が、静脈内、筋肉内、または皮下経路により投与されることに適する、請求項18に記載の医薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TNTN2010/0566 | 2010-12-03 | ||
TNP2010000566A TN2010000566A1 (en) | 2010-12-03 | 2010-12-03 | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
PCT/IB2011/000960 WO2012073077A1 (en) | 2010-12-03 | 2011-05-06 | Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013544275A JP2013544275A (ja) | 2013-12-12 |
JP5897592B2 true JP5897592B2 (ja) | 2016-03-30 |
Family
ID=54696113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013541436A Expired - Fee Related JP5897592B2 (ja) | 2010-12-03 | 2011-05-06 | 葉酸−ラミプリルの組合せ:細胞保護性、神経保護性、および網膜保護性の眼科用組成物 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20130317036A1 (ja) |
EP (1) | EP2646010B1 (ja) |
JP (1) | JP5897592B2 (ja) |
CN (1) | CN103338758B (ja) |
AU (1) | AU2011334617B2 (ja) |
CA (1) | CA2819628C (ja) |
ES (1) | ES2770410T3 (ja) |
PL (1) | PL2646010T3 (ja) |
RU (1) | RU2602738C2 (ja) |
TN (1) | TN2010000566A1 (ja) |
WO (1) | WO2012073077A1 (ja) |
ZA (1) | ZA201304026B (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
WO2013041967A2 (en) | 2011-09-20 | 2013-03-28 | Altavista Instituto De Investigation Medica S.A.S | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
TN2016000259A1 (en) * | 2016-06-27 | 2017-10-06 | Rekik Raouf | Salbutamol (albuterol) eye protective medicament. |
EP3583940A1 (en) * | 2016-08-11 | 2019-12-25 | Intrabio Ltd | Therapeutic agents for neurodegenerative diseases |
CN108452309B (zh) * | 2018-03-05 | 2019-08-23 | 佳木斯大学附属第一医院 | 一种用于预防或治疗视神经炎的药物组合物及其制备方法 |
RU2717343C1 (ru) * | 2019-03-01 | 2020-03-23 | Евгений Владимирович Плотников | Средство, обладающее цитопротекторным действием |
CN114917345A (zh) * | 2021-04-07 | 2022-08-19 | 北京蛋白质组研究中心 | 靶向soat1蛋白的化合物在制备预防和/或治疗肝癌药物中的应用 |
AU2022300058A1 (en) * | 2021-06-24 | 2024-02-01 | Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. | Application of folic acid derivatives in preparation of drugs for treating contact lens discomfort and xerophthalmia |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804603A (en) | 1993-11-26 | 1998-09-08 | National Science Council | Synthesized β-adrenergic blockers derivatives of guaiacol |
BR9910947A (pt) * | 1998-06-05 | 2001-03-06 | Warner Lambert Co | Estabilização de composições que contêm inibidores de ace utilizando óxido de magnésio |
US6207190B1 (en) * | 1998-08-13 | 2001-03-27 | Chronorx, Llc | Dosage forms for the treatment of the chronic glaucomas |
DE60041765D1 (de) * | 1999-06-16 | 2009-04-23 | Rekik Elyes Ben Mohamed Raouf | RETINA PROTEKTIVE OPHTHALMOLOGISCHEN ARZNEIMITTELN enthaltend ramipril oder ramiprilat |
US7335803B2 (en) | 2001-10-19 | 2008-02-26 | Allergan, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
US6583152B2 (en) * | 2001-04-30 | 2003-06-24 | Dexgen Pharmaceuticals, Inc. | Composition for reducing the risk or progression of cardiovascular diseases |
AU2002355419A1 (en) * | 2001-08-06 | 2003-02-24 | Genomed, Llc | Methods and compositions for treating diseases associated with excesses in ace |
US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US20030099724A1 (en) * | 2001-11-16 | 2003-05-29 | Turner Oliver E. | Compounds for prevention of diabetic retinopathy |
US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7351739B2 (en) * | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
US20060035864A1 (en) * | 2004-08-10 | 2006-02-16 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
WO2006085128A1 (en) * | 2005-02-09 | 2006-08-17 | Wockhardt Limited | Cardiovascular therapeutic combinations |
WO2007014308A1 (en) * | 2005-07-27 | 2007-02-01 | Achillion Pharmaceuticals, Inc. | 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents |
ES2300188B1 (es) * | 2006-05-24 | 2009-05-01 | Ferrer Internacional, S.A. | Comprimido bicapa para la prevencion de los accidentes cardiovasculares. |
CN101176788B (zh) * | 2006-11-11 | 2011-06-15 | 深圳奥萨医药有限公司 | Ace抑制剂/利尿剂/叶酸联用的药物组合物及其用途 |
WO2008132756A1 (en) * | 2007-05-01 | 2008-11-06 | Lupin Limited | Stable pharmaceutical compositions of ramipril |
CN101396561A (zh) * | 2007-09-28 | 2009-04-01 | 北京华安佛医药研究中心有限公司 | 含有acei的组合物在制备治疗高同型半胱氨酸血症损伤及其相关疾病的药物中的用途 |
CN101590084B (zh) * | 2008-05-29 | 2012-12-05 | 北京奥萨医药研究中心有限公司 | 含有血管紧张素转化酶抑制剂、b族维生素和银杏叶提取物的药物组合物 |
CN101322743A (zh) * | 2008-08-01 | 2008-12-17 | 李翔 | 一种能修复眼部病变损伤改善视力疲劳的制剂及其制备方法 |
CA2836445C (en) * | 2010-06-25 | 2019-06-11 | Global Healthcare Focus, Llc | Methods of treating optic disorders |
-
2010
- 2010-12-03 TN TNP2010000566A patent/TN2010000566A1/fr unknown
-
2011
- 2011-05-06 US US13/991,286 patent/US20130317036A1/en not_active Abandoned
- 2011-05-06 CN CN201180066768.3A patent/CN103338758B/zh not_active Expired - Fee Related
- 2011-05-06 PL PL11724029T patent/PL2646010T3/pl unknown
- 2011-05-06 JP JP2013541436A patent/JP5897592B2/ja not_active Expired - Fee Related
- 2011-05-06 ES ES11724029T patent/ES2770410T3/es active Active
- 2011-05-06 RU RU2013125146/15A patent/RU2602738C2/ru active
- 2011-05-06 WO PCT/IB2011/000960 patent/WO2012073077A1/en active Application Filing
- 2011-05-06 EP EP11724029.1A patent/EP2646010B1/en active Active
- 2011-05-06 CA CA2819628A patent/CA2819628C/en active Active
- 2011-05-06 AU AU2011334617A patent/AU2011334617B2/en not_active Ceased
-
2013
- 2013-05-31 ZA ZA2013/04026A patent/ZA201304026B/en unknown
-
2015
- 2015-01-16 US US14/599,223 patent/US20150133455A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2819628C (en) | 2019-12-03 |
AU2011334617A1 (en) | 2013-06-20 |
JP2013544275A (ja) | 2013-12-12 |
AU2011334617B2 (en) | 2017-01-12 |
US20150133455A1 (en) | 2015-05-14 |
EP2646010B1 (en) | 2019-11-13 |
US20130317036A1 (en) | 2013-11-28 |
CN103338758B (zh) | 2017-12-12 |
RU2602738C2 (ru) | 2016-11-20 |
WO2012073077A1 (en) | 2012-06-07 |
ZA201304026B (en) | 2014-02-26 |
CA2819628A1 (en) | 2012-06-07 |
AU2011334617A2 (en) | 2013-08-01 |
RU2013125146A (ru) | 2015-01-10 |
CN103338758A (zh) | 2013-10-02 |
TN2010000566A1 (en) | 2012-05-24 |
EP2646010A1 (en) | 2013-10-09 |
PL2646010T3 (pl) | 2020-06-01 |
ES2770410T3 (es) | 2020-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5897592B2 (ja) | 葉酸−ラミプリルの組合せ:細胞保護性、神経保護性、および網膜保護性の眼科用組成物 | |
EP2262476B1 (en) | Drug delivery to the anterior and posterior segments of the eye using eye drops. | |
US20220184057A1 (en) | Combination treatment of ocular inflammatory disorders and diseases | |
WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
JP5212849B2 (ja) | 眼内血管新生及び/又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 | |
RU2012151575A (ru) | Нейропротекторное и ретинопротекторное средство n-ацетил-dl-лейцин | |
US10973758B2 (en) | Methods of eye treatment using therapeutic compositions containing dipyridamole | |
US20200188405A1 (en) | Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma | |
TW202337462A (zh) | 採用長春西汀治療近視的方法 | |
Croasdell | Association for Research in Vision and Ophthalmology (ARVO)-2016 Annual Meeting. Seattle, Washington, USA-April 29-May 5, 2016 | |
US20140213605A1 (en) | Methods for treating eye disorders using opioid receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130801 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140501 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150420 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150714 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151020 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160201 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160302 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5897592 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |